Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip De Keyser

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Clinical and Experimental Rheumatology|July 10, 2019
Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathyYves Piette, Maxime De Sloovere, Stien Vandendriessche, et al.
Rheumatology (Oxford, England)|February 5, 2016
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseasesVanessa Smith, Sam Beeckman, Ariane L Herrick, et al.
Arthritis Research & Therapy|September 19, 2006
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activityBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Seminars in Arthritis and Rheumatism|August 17, 2021
Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort studyEls Vandecasteele, Karin Melsens, Amber Vanhaecke, et al.
Arthritis Research & Therapy|October 7, 2005
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatmentBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
The Journal of Rheumatology|October 11, 2002
Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profilesJieruo Gu, Markus Rihl, Elisabeth Märker-Hermann, et al.
Acta Clinica Belgica|September 12, 2017
Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosisKarin Melsens, Els Vandecasteele, Ellen Deschepper, et al.
Arthritis and Rheumatism|December 31, 2005
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysisFotini B Karassa, Antonella Afeltra, Ales Ambrozic, et al.
Annals of the Rheumatic Diseases|September 26, 2009
Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trialRobert B M Landewé, Jos G A Houbiers, Filip Van den Bosch, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi techniqueJoerg H W Distler, Suzana Jordan, Paolo Airo, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Clinical and Experimental Rheumatology|July 10, 2019
Pitfalls in the detection of myositis specific antibodies by lineblot in clinically suspected idiopathic inflammatory myopathyYves Piette, Maxime De Sloovere, Stien Vandendriessche, et al.
Rheumatology (Oxford, England)|February 5, 2016
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseasesVanessa Smith, Sam Beeckman, Ariane L Herrick, et al.
Arthritis Research & Therapy|September 19, 2006
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activityBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
Seminars in Arthritis and Rheumatism|August 17, 2021
Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort studyEls Vandecasteele, Karin Melsens, Amber Vanhaecke, et al.
Arthritis Research & Therapy|October 7, 2005
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatmentBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
The Journal of Rheumatology|October 11, 2002
Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profilesJieruo Gu, Markus Rihl, Elisabeth Märker-Hermann, et al.
Acta Clinica Belgica|September 12, 2017
Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosisKarin Melsens, Els Vandecasteele, Ellen Deschepper, et al.
Arthritis and Rheumatism|December 31, 2005
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysisFotini B Karassa, Antonella Afeltra, Ales Ambrozic, et al.
Annals of the Rheumatic Diseases|September 26, 2009
Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trialRobert B M Landewé, Jos G A Houbiers, Filip Van den Bosch, et al.
Clinical and Experimental Rheumatology|May 19, 2011
Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi techniqueJoerg H W Distler, Suzana Jordan, Paolo Airo, et al.
Pageof 11